stockrowScholar Rock Holding Corporation
SRRK Healthcare Biotechnology
Scholar Rock Holding Corporation’s revenue for fiscal 2022 (year ended December 2022) was $33.2 million.
- EPS
- +14.3%
- Free cash flow
- +8.88%
- Total debt
- +294.3%
Quarter to June 2026, against a year earlier
Follow SRRK
Alert me
Scholar Rock Holding Corporation (SRRK) EBITDA
Scholar Rock Holding Corporation's EBITDA for fiscal 2025 was −$386.6M, compared with −$255.2M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$405.8M. Over the past ten years it has ranged from −$386.6M (fiscal 2025) to −$15.8M (fiscal 2016) — the current reading is the lowest in ten years. EBITDA has fallen for 9 consecutive fiscal years. Scholar Rock Holding Corporation ranks 565th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$386.6M | — |
| FY2024 | −$255.2M | — |
| FY2023 | −$174.4M | — |
| FY2022 | −$132.8M | — |
| FY2021 | −$126.0M | — |
| FY2020 | −$85.5M | — |
| FY2019 | −$54.6M | — |
| FY2018 | −$50.2M | — |
| FY2017 | −$24.4M | — |
| FY2016 | −$15.8M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$108.6M | — |
| Mar 2026 | −$101.8M | — |
| Dec 2025 | −$91.6M | — |
| Sep 2025 | −$103.8M | — |
| 32 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | $191.8M |
| MANE Veradermics Incorporated compare | −$88.4M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$118.6M |
| KOD Kodiak Sciences Inc. compare | −$220.8M |
| CGON CG Oncology, Inc. compare | −$250.7M |
| ERAS Erasca, Inc. compare | −$302.6M |
| COGT Cogent Biosciences, Inc. compare | −$388.7M |
| SRRK Scholar Rock Holding Corporation | −$405.8M |
| IMVT Immunovant, Inc. compare | −$565.6M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on SRRK
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement